Let's Talk Innovation

Let's Talk

You are here

Collaboration with Modern Biosciences to advance the development of novel compounds for RA

Innovation Center December 1st, 2014

Affecting around 165 million people worldwide, rheumatoid arthritis (RA) is a chronic, immune-related disease causing inflammation in the joints that can lead to severe pain, swelling and stiffness. RA can be life-altering, as progressive erosion of the joints over time can hinder everyday activities and in some cases lead to long-term disability.

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

Innovation Center August 25th, 2014

Today, Cilag GmbH International, an affiliate of Janssen Pharmaceutical Companies of Johnson & Johnson, announced the acquisition of Covagen AG, a privately-held biopharmaceutical company specializing in the development of multispecific protein therapeutics.  The acquisition strengthens Janssen’s Immunology portfolio through the addition of COVA322, a Phase 1b clinical candidate, and the company’s biotechnology capabilities through the addition of the FynomAb® Technology Platform.

Subscribe to RSS - Ian Anderson's blog